Literature DB >> 15288982

Long-term effects of mitomycin C in pterygium surgery on scleral thickness and the conjunctival epithelium.

Abraham Solomon1, Igor Kaiserman, Frederick D Raiskup, David Landau, Joseph Frucht-Pery.   

Abstract

PURPOSE: To evaluate the long-term effects of intraoperative application of mitomycin C on the scleral thickness and the conjunctival epithelium at the surgical site of pterygium excision.
DESIGN: Prospective observational case series. PARTICIPANTS: Twenty-four patients who underwent excision of primary pterygium with intraoperative mitomycin C in our department during the year 1996.
METHODS: Patients were evaluated by slit-lamp biomicroscopy, impression cytology, and high-frequency ultrasonography. Impression cytology was performed by applying a small nitrocellulose filter paper for a few seconds at the excision area and for a few seconds at the opposite perilimbal area, and subjecting the specimens to the periodic acid-Schiff-Gill modified Papanicolaou staining protocol. The morphology of the conjunctival epithelium and goblet cell density (GCD) were recorded. High-frequency ultrasound was performed at the same sites, and the scleral thickness was measured at a distance of 1 mm from the limbus. MAIN OUTCOME MEASURES: Goblet cell density, conjunctival epithelial morphology, and the scleral thickness at the operated and nonoperated sites.
RESULTS: All patients had successful pterygium removal with no corneal recurrence after a mean follow-up of 77.2+/-3.9 months (range, 72-84). Impression cytology revealed normal nongoblet conjunctival epithelial cells at the excision area, with a 4-fold decrease in the GCD at the excision area when compared with the contralateral nonoperated site (296+/-120 cells/mm(2) and 1183+/-310 cells/mm(2), respectively; P = 0.0036). No differences were noted between the scleral thicknesses at the operated site (750+/-70 microm) and the opposite site (740+/-80 microm) (P = 0.84).
CONCLUSIONS: A single application of mitomycin C after pterygium excision is not associated with reduction in scleral thickness more than 6 years postoperatively. The conjunctival epithelium retains its normal phenotype, with a marked reduction of the GCD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288982     DOI: 10.1016/j.ophtha.2004.02.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Prophylactic removal and microbiological evaluation of calcified plaques after pterygium surgery.

Authors:  Tai Jun Kim; Hyuk Jin Choi; Mee Kum Kim; Won Ryang Wee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-15       Impact factor: 3.117

2.  Comparison of mitomycin C and limbal-conjunctival autograft in the prevention of pterygial recurrence in Turkish patients: A one-year, randomized, assessor-masked, controlled trial.

Authors:  Seyhmus Ari; Ihsan Caca; Zennure Özdemir Yildiz; Yildirim Bayezit Sakalar; Eyüp Dogan
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

3.  [Recurrence rates after pterygium excision with sliding conjunctival flap versus free conjunctival autograft].

Authors:  S Müller; J Stahn; K Schmitz; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

Review 4.  Delayed manifestation of bilateral scleral thinning after I-BRITE(®) procedure and review of literature for cosmetic eye-whitening procedures.

Authors:  Majid Moshirfar; Michael V McCaughey; Carlton R Fenzl; Luis Santiago-Caban; Gregory D Kramer; Nick Mamalis
Journal:  Clin Ophthalmol       Date:  2015-03-04

5.  Tailored treatment for the management of scleral necrosis following pterygium excision.

Authors:  Linna Lu; Shiqiong Xu; Shengfang Ge; Chunyi Shao; Zi Wang; Xuyang Weng; Wenjuan Lu; Xinhua Wu; Yao Fu; Xianqun Fan
Journal:  Exp Ther Med       Date:  2017-01-12       Impact factor: 2.447

6.  Necrotizing scleritis as a complication of cosmetic eye whitening procedure.

Authors:  Theresa G Leung; James P Dunn; Esen K Akpek; Jennifer E Thorne
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.